The Chemours Company: income tax expense or benefit
Income tax expense or benefit for The Chemours Company. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All The Chemours Company financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 109,000,000 | USD | 2026-02-24 | 10-K · 0001193125-26-065201 |
| 2024-01-01 | 2024-12-31 | 37,000,000 | USD | 2026-02-24 | 10-K · 0001193125-26-065201 |
| 2023-01-01 | 2023-12-31 | -66,000,000 | USD | 2026-02-24 | 10-K · 0001193125-26-065201 |
| 2022-01-01 | 2022-12-31 | 163,000,000 | USD | 2025-02-18 | 10-K · 0000950170-25-021787 |
| 2021-01-01 | 2021-12-31 | 68,000,000 | USD | 2024-03-27 | 10-K · 0000950170-24-037171 |
| 2020-01-01 | 2020-12-31 | -40,000,000 | USD | 2023-02-10 | 10-K · 0000950170-23-002467 |
| 2019-01-01 | 2019-12-31 | -72,000,000 | USD | 2022-02-11 | 10-K · 0001564590-22-004791 |
| 2018-01-01 | 2018-12-31 | 159,000,000 | USD | 2021-02-12 | 10-K · 0001564590-21-005805 |
| 2017-01-01 | 2017-12-31 | 165,000,000 | USD | 2020-02-14 | 10-K · 0001564590-20-004829 |
| 2016-01-01 | 2016-12-31 | -18,000,000 | USD | 2019-02-15 | 10-K · 0001564590-19-003090 |
| 2015-01-01 | 2015-12-31 | -98,000,000 | USD | 2018-02-16 | 10-K · 0001564590-18-002325 |
| 2014-01-01 | 2014-12-31 | 149,000,000 | USD | 2017-02-17 | 10-K · 0001564590-17-001763 |
| 2013-01-01 | 2013-12-31 | 152,000,000 | USD | 2016-02-25 | 10-K · 0001627223-16-000066 |
Related financial histories
- The Chemours Company: total assets
- The Chemours Company: total liabilities
- The Chemours Company: stockholders equity
- The Chemours Company: cash and cash equivalents
- The Chemours Company: net income or loss
- The Chemours Company: operating cash flow
- The Chemours Company: capital expenditure payments
- The Chemours Company: revenue
- The Chemours Company: contract revenue excluding tax
- The Chemours Company: financing cash flow
- The Chemours Company: investing cash flow
- The Chemours Company: retained earnings or deficit
- The Chemours Company: basic weighted-average shares
- The Chemours Company: diluted weighted-average shares
- The Chemours Company: basic earnings per share
- The Chemours Company: diluted earnings per share
- The Chemours Company: net property, plant and equipment
- The Chemours Company: share-based compensation expense
- The Chemours Company: current assets
- The Chemours Company: interest expense
- The Chemours Company: current liabilities
- The Chemours Company: current accounts payable
- The Chemours Company: goodwill carrying amount
- The Chemours Company: net finite-lived intangible assets
- The Chemours Company: net current accounts receivable
- The Chemours Company: common-stock repurchase payments
- The Chemours Company: operating expenses
- The Chemours Company: net inventory
- The Chemours Company: gross profit
- The Chemours Company: selling, general and administrative expense
- The Chemours Company: research and development expense
Inspect the source
- Entity
- The Chemours Company / CIK 0001627223
- Captured
- 2026-09-21T17:22:08.501Z
- SEC response SHA-256
a9767e28b16e6bc2a1915d2db9d049db0a8a49ad9444b46cef2ef105d657541e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001627223.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))